Who can get a prescription for Ozempic in the EU?
Ozempic (semaglutide) is a prescription-only GLP-1 receptor agonist approved in the EU for adults with type 2 diabetes under defined clinical criteria. In this episode, we explain eligibility, assessment requirements, and when prescriptions may be declined.
In this episode, we cover:
• What Ozempic is (a GLP-1 receptor agonist for type 2 diabetes)
• EU-approved indication: adults with insufficient glycaemic control
• HbA1c thresholds and prior treatment requirements
• Use alongside diet, exercise, and other glucose-lowering medicines
• Differences between Ozempic and weight-specific semaglutide brands
• Contraindications: type 1 diabetes, certain thyroid conditions
• Required monitoring: HbA1c, kidney function, side effects
• Cardiovascular risk assessment before prescribing
• Situations where requests may be declined
Doctors assess confirmed type 2 diabetes diagnosis, HbA1c levels, BMI, kidney function, pancreatitis history, thyroid cancer risk, medication history, and cardiovascular profile before prescribing. Ozempic is not approved for cosmetic weight loss. Severe abdominal pain, persistent vomiting, or symptoms of hypoglycaemia require medical evaluation.
This episode reflects how diabetes treatment decisions are reviewed within structured medical assessment in European telemedicine at Mobi Doctor.
Read the full medical guide here:
https://www.mobidoctor.eu/blog/who-can-get-a-prescription-for-ozempic-in-the-eu